Corrigendum: Alternative splicing promotes tumour aggressiveness and drug resistance in African American prostate cancer (Nature Communications (2017) 8 (15921) DOI: 10.1038/ncomms15921);Alternative splicing promotes tumour aggressiveness and drug resistance in African American prostate cancer

Nature Communications

Volumn 8, Issue , 2017, Pages

  Wang, Bi Dar ^a,b   Ceniccola, Kristin ^a   Hwang, Sujin ^a   Andrawis, Ramez ^a   Horvath, Anelia ^a   Freedman, Jennifer A ^c   Olender, Jacqueline ^a   Knapp, Stefan ^d,e   Ching, Travers ^f   Garmire, Lana ^f   Patel, Vyomesh ^g   Garcia Blanco, Mariano A ^h   Patierno, Steven R ^c   Lee, Norman H ^a  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b UNIVERSITY OF MARYLAND EASTERN SHORE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^g NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^h University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4 INTEGRIN; ATM PROTEIN; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 3; IDELALISIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE DELTA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P85; PROTEIN S6; SCATTER FACTOR RECEPTOR; TUBERIN; UNCLASSIFIED DRUG; VASCULOTROPIN; WORTMANNIN; GUANINE NUCLEOTIDE EXCHANGE FACTOR; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PIK3CD PROTEIN, HUMAN; RASGRP2 PROTEIN, HUMAN;

AGGRESSION; CELLS AND CELL COMPONENTS; DRUG RESISTANCE; GENE EXPRESSION; GENETIC ANALYSIS; INHIBITOR; LABORATORY METHOD; MOLECULAR ANALYSIS; TUMOR;

ADULT; AFRICAN AMERICAN; ALTERNATIVE RNA SPLICING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RESISTANCE; CANCER SURVIVAL; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME ACTIVATION; ENZYME ACTIVITY; EUROPEAN AMERICAN; FUNCTIONAL GENOMICS; GENE OVEREXPRESSION; GENOME-WIDE ASSOCIATION STUDY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INTRACELLULAR SIGNALING; LUNG METASTASIS; MALE; MIDDLE AGED; MOLECULAR CLONING; MOUSE; NONHUMAN; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT; AGED; ANIMAL; DRUG RESISTANCE; GENETICS; METABOLISM; PATHOLOGY; PROSTATE TUMOR; SCID MOUSE; TUMOR CELL LINE; TUMOR INVASION; XENOGRAFT;

AFRICAN AMERICANS; AGED; ALTERNATIVE SPLICING; ANIMALS; CELL LINE, TUMOR; CLASS I PHOSPHATIDYLINOSITOL 3-KINASES; DRUG RESISTANCE, NEOPLASM; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HETEROGRAFTS; HUMANS; MALE; MICE; MICE, SCID; MIDDLE AGED; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3;

EID: 85021676602     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms16161     Document Type: Erratum

References (70)

1. Jemal, A. et al. Cancer statistics, 2007. CA Cancer. J. Clin. 57, 43-66 (2007).
2. Reddy, S., Shapiro, M., Morton, Jr. R. & Brawley, O. W. Prostate cancer in black and white Americans. Cancer Metastasis. Rev. 22, 83-86 (2003).
3. Powell, I. J. Epidemiology and pathophysiology of prostate cancer in African-American men. J. Urol. 177, 444-449 (2007).
4. Jones, B. A. et al. Explaining the race difference in prostate cancer stage at diagnosis. Cancer Epidemiol. Biomarkers Prev. 17, 2825-2834 (2008).
5. Evans, S., Metcalfe, C., Ibrahim, F., Persad, R. & Ben-Shlomo, Y. Investigating Black-White differences in prostate cancer prognosis: A systematic review and meta-analysis. Int. J. Cancer. 123, 430-435 (2008).
6. Kittles, R. A. et al. A common nonsense mutation in EphB2 is associated with prostate cancer risk in African American men with a positive family history. J. Med. Genet. 43, 507-511 (2006).
7. Powell, I. J. & Bollig-Fischer, A. Minireview: the molecular and genomic basis for prostate cancer health disparities. Mol. Endocrinol. 27, 879-891 (2013).
8. Wallace, T. A. et al. Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res. 68, 927-936 (2008).
9. Wang, B. D. et al. Identification and functional validation of reciprocal microRNA-mRNA pairings in African American prostate cancer disparities. Clin. Cancer Res. 21, 4970-4984 (2015).
10. Wang, B. D. et al. Androgen receptor-target genes in african american prostate cancer disparities. Prostate Cancer 2013, 763569 (2013).
11. Pan, Q., Shai, O., Lee, L. J., Frey, B. J. & Blencowe, B. J. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat. Genet. 40, 1413-1415 (2008).
12. David, C. J. & Manley, J. L. Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev. 24, 2343-2364 (2010).
13. Chen, J. & Weiss, W. A. Alternative splicing in cancer: implications for biology and therapy. Oncogene 34, 1-14 (2015).
14. Wang, J. et al. Pleiotropic biological activities of alternatively spliced TMPRSS2/ ERG fusion gene transcripts. Cancer Res. 68, 8516-8524 (2008).
15. Mercatante, D. R., Mohler, J. L. & Kole, R. Cellular response to an antisensemediated shift of Bcl-x pre-mRNA splicing and antineoplastic agents. J. Biol. Chem. 277, 49374-49382 (2002).
16. Rajan, P., Elliott, D. J., Robson, C. N. & Leung, H. Y. Alternative splicing and biological heterogeneity in prostate cancer. Nat. Rev. Urol. 6, 454-460 (2009).
17. Akgul, C., Moulding, D. A. & Edwards, S. W. Alternative splicing of Bcl-2-related genes: functional consequences and potential therapeutic applications. Cell. Mol. Life Sci. 61, 2189-2199 (2004).
18. Sun, A. et al. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression. Prostate 68, 453-461 (2008).
19. Bauman, J. A., Li, S. D., Yang, A., Huang, L. & Kole, R. Anti-tumor activity of splice-switching oligonucleotides. Nucleic Acids Res. 38, 8348-8356 (2010).
20. Oltean, S. et al. Alternative inclusion of fibroblast growth factor receptor 2 exon IIIc in Dunning prostate tumors reveals unexpected epithelial mesenchymal plasticity. Proc. Natl Acad. Sci. USA 103, 14116-14121 (2006).
21. Demichelis, F. et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26, 4596-4599 (2007).
22. Hu, Y. et al. Delineation of TMPRSS2-ERG splice variants in prostate cancer. Clin. Cancer Res. 14, 4719-4725 (2008).
23. Heinlein, C. A. & Chang, C. Androgen receptor in prostate cancer. Endocr. Rev. 25, 276-308 (2004).
24. Antonarakis, E. S. et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med. 371, 1028-1038 (2014).
25. Hu, R. et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 69, 16-22 (2009).
26. Fan, W., Stirewalt, D. L., Radich, J. P. & Zhao, L. Comparison of two methods for detecting alternative splice variants using genechip((R)) exon arrays. Int. J. Biomed. Sci. 7, 172-180 (2011).
27. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068 (2008).
28. Ding, L. et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455, 1069-1075 (2008).
29. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615 (2012).
30. Boller, D. et al. Targeting the phosphoinositide 3-kinase isoform p110delta impairs growth and survival in neuroblastoma cells. Clin. Cancer Res. 14, 1172-1181 (2008).
31. Jiang, X., Chen, S., Asara, J. M. & Balk, S. P. Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits. J. Biol. Chem. 285, 14980-14989 (2010).
32. Knobbe, C. B. & Reifenberger, G. Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-30-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas. Brain Pathol. 13, 507-518 (2003).
33. Tzenaki, N. et al. High levels of p110delta PI3K expression in solid tumor cells suppress PTEN activity, generating cellular sensitivity to p110delta inhibitors through PTEN activation. FASEB J. 26, 2498-2508 (2012).
34. Glickman, M., Malek, R. L., Kwitek-Black, A. E., Jacob, H. J. & Lee, N. H. Molecular cloning, tissue-specific expression, and chromosomal localization of a novel nerve growth factor-regulated G-protein-coupled receptor, nrg-1. Mol. Cell Neurosci. 14, 141-152 (1999).
35. Korenchuk, S. et al. VCaP, a cell-based model system of human prostate cancer. In Vivo 15, 163-168 (2001).
36. Navone, N. M. et al. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin. Cancer Res. 3, 2493-2500 (1997).
37. Herman, S. E. et al. Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 116, 2078-2088 (2010).
38. Lannutti, B. J. et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 117, 591-594 (2011).
39. Fruman, D. A. & Rommel, C. PI3Kdelta inhibitors in cancer: rationale and serendipity merge in the clinic. Cancer Discov. 1, 562-572 (2011).
40. Yang, J. et al. Pathological axonal death through a MAPK cascade that triggers a local energy deficit. Cell 160, 161-176 (2015).
41. Berndt, A. et al. The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors. Nat. Chem. Biol. 6, 117-124 (2010).
42. Geering, B., Cutillas, P. R., Nock, G., Gharbi, S. I. & Vanhaesebroeck, B. Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers. Proc. Natl Acad. Sci. USA 104, 7809-7814 (2007).
43. Fry, M. J. et al. Purification and characterization of a phosphatidylinositol 3-kinase complex from bovine brain by using phosphopeptide affinity columns. Biochem. J. 288, 383-393 (1992).
44. Woscholski, R., Dhand, R., Fry, M. J., Waterfield, M. D. & Parker, P. J. Biochemical characterization of the free catalytic p110 alpha and the complexed heterodimeric p110 alpha.p85 alpha forms of the mammalian phosphatidylinositol 3-kinase. J. Biol. Chem. 269, 25067-25072 (1994).
45. Fransson, S. et al. p37delta is a new isoform of PI3K p110delta that increases cell proliferation and is overexpressed in tumors. Oncogene 31, 3277-3286 (2012).
46. Arcaro, A. & Wymann, M. P. Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. Biochem. J. 296 Pt 2 297-301 (1993).
47. Yang, Y. et al. Dysregulation of microRNA-212 promotes castration resistance via hnRNPH1-mediated regulation of AR and AR-V7: implications for racial disparity of prostate cancer. Clin. Cancer Res. 22, 1744-1756 (2016).
48. Modrek, B., Resch, A., Grasso, C. & Lee, C. Genome-wide detection of alternative splicing in expressed sequences of human genes. Nucleic Acids Res. 29, 2850-2859 (2001).
49. Sorek, R., Shamir, R. & Ast, G. How prevalent is functional alternative splicing in the human genome Trends Genet. 20, 68-71 (2004).
50. Blencowe, B. J. Alternative splicing: new insights from global analyses. Cell 126, 37-47 (2006).
51. Courtney, K. D., Corcoran, R. B. & Engelman, J. A. The PI3K pathway as drug target in human cancer. J. Clin. Oncol. 28, 1075-1083 (2010).
52. Ciraolo, E., Morello, F. & Hirsch, E. Present and future of PI3K pathway inhibition in cancer: perspectives and limitations. Curr. Med. Chem. 18, 2674-2685 (2011).
53. Clayton, E. et al. A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation. J. Exp. Med. 196, 753-763 (2002).
54. Jou, S. T. et al. Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex. Mol. Cell. Biol. 22, 8580-8591 (2002).
55. Castillo, J. J., Furman, M. & Winer, E. S. CAL-101: A phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies. Expert Opin. Investig. Drugs 21, 15-22 (2012).
56. Nakazawa, M., Antonarakis, E. S. & Luo, J. Androgen receptor splice variants in the era of enzalutamide and abiraterone. Horm. Cancer 5, 265-273 (2014).
57. Shi, H. et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 4, 80-93 (2014).
58. Berndt, A. et al. The p110delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors. Nat. Chem. Biol. 6, 117-124 (2010).
59. Gopal, A. K. et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N. Engl. J. Med. 370, 1008-1018 (2014).
60. Brown, J. R. et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood 123, 3390-3397 (2014).
61. Shah, A. & Mangaonkar, A. Idelalisib: A novel PI3Kdelta inhibitor for chronic lymphocytic leukemia. Ann. Pharmacother. 49, 1162-1170 (2015).
62. Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M. & Bilanges, B. The emerging mechanisms of isoform-specific PI3K signalling. Nat. Rev. Mol. Cell Biol. 11, 329-341 (2010).
63. Yu, J. et al. Regulation of the p85/p110 phosphatidylinositol 30-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit. Mol. Cell Biol. 18, 1379-1387 (1998).
64. Chan, T. O. et al. Small GTPases and tyrosine kinases coregulate a molecular switch in the phosphoinositide 3-kinase regulatory subunit. Cancer Cell 1, 181-191 (2002).
65. Jaiswal, B. S. et al. Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. Cancer Cell 16, 463-474 (2009).
66. Amzel, L. M. et al. Structural comparisons of class I phosphoinositide 3-kinases. Nat. Rev. Cancer 8, 665-669 (2008).
67. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Statist. Soc. 57, 289-300 (1995).
68. Fukuda, H. et al. Host-derived MMP-13 exhibits a protective role in lung metastasis of melanoma cells by local endostatin production. Br. J. Cancer 105, 1615-1624 (2011).
69. Kim, H., Bi, Y., Pal, S., Gupta, R. & Davuluri, R. V. IsoformEx: isoform level gene expression estimation using weighted non-negative least squares from mRNA-Seq data. BMC Bioinformatics 12, 305 (2011).
70. Huang, S., Yee, C., Ching, T., Yu, H. & Garmire, L. X. A novel model to combine clinical and pathway-based transcriptomic information for the prognosis prediction of breast cancer. PLoS Comput. Biol. 10, e1003851 (2014).